

In the Claims

1-24 (canceled).

25 (previously presented). A conjugate comprising in the form of a fusion protein:

(a) a first region comprising the homeodomain of antennapedia ~~or a functional variant thereof~~; and

(b) a second region not naturally associated with the first region, wherein the second region ~~comprises~~ consists of a protein of at least 100 amino acids; and wherein ~~at least the first region and the second region are~~ is non-denatured.

26-28 (canceled).

29 (previously presented). The conjugate according to claim 25, wherein the second region comprises a functional or regulatory protein.

30 (previously presented). The conjugate according to claim 25, wherein the second region comprises an antigen.

31 (previously presented). The conjugate according to claim 25, wherein the second region comprises a DNA binding domain.

32 (canceled).

33 (previously presented). The conjugate according to claim 31, wherein the DNA binding domain is from a histone protein or a transcription factor.

34 (previously presented). The conjugate according to claim 33, wherein the transcription factor is GAL4.

35-36 (canceled).

37 (previously presented). The conjugate according to claim 25, provided in a pharmaceutically-acceptable carrier.

38-39 (canceled).

40 (presently presented). A conjugate prepared by a method comprising the steps:

(i) culturing a host cell transformed with an expression vector comprising a nucleic acid encoding the conjugate of claim 25 under conditions which provide for the expression of the conjugate within the host cell; and

(ii) recovering the conjugate by affinity purification under non-denaturing conditions.

41 (presently presented). The conjugate prepared according to claim 40, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.

42-45 (canceled).

46 (new). The composition according to claim 25, wherein the composition comprises an amino acid tail that binds to an immobilised substrate.